These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26224766)

  • 1. Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.
    Cavaleri M; Manolis E
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S1-4. PubMed ID: 26224766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
    Pasipanodya JG; Nuermberger E; Romero K; Hanna D; Gumbo T
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S10-7. PubMed ID: 26224767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.
    Romero K; Clay R; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S5-9. PubMed ID: 26224771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Sensitivity Testing of Mycobacterium tuberculosis Growing in a Hollow Fiber Bioreactor.
    Mason AB; Dartois V
    Methods Mol Biol; 2021; 2314():715-731. PubMed ID: 34235677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
    Gumbo T; Pasipanodya JG; Nuermberger E; Romero K; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S18-24. PubMed ID: 26224768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Hollow Fiber System Model in the Nonclinical Evaluation of Antituberculosis Drug Regimens.
    Chilukuri D; McMaster O; Bergman K; Colangelo P; Snow K; Toerner JG
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S32-3. PubMed ID: 26224770
    [No Abstract]   [Full Text] [Related]  

  • 7. Preclinical Efficacy Testing of New Drug Candidates.
    Nuermberger EL
    Microbiol Spectr; 2017 Jun; 5(3):. PubMed ID: 28643624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.
    Gumbo T; Angulo-Barturen I; Ferrer-Bazaga S
    J Infect Dis; 2015 Jun; 211 Suppl 3():S96-S106. PubMed ID: 26009618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs.
    Gumbo T; Alffenaar JC
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S267-S273. PubMed ID: 30496455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current challenges in drug discovery for tuberculosis.
    Kumar A; Chettiar S; Parish T
    Expert Opin Drug Discov; 2017 Jan; 12(1):1-4. PubMed ID: 27797593
    [No Abstract]   [Full Text] [Related]  

  • 11. The future for early-stage tuberculosis drug discovery.
    Zuniga ES; Early J; Parish T
    Future Microbiol; 2015; 10(2):217-29. PubMed ID: 25689534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB.
    Vaddady PK; Lee RE; Meibohm B
    Future Med Chem; 2010 Aug; 2(8):1355-69. PubMed ID: 21359155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges and opportunities in tuberculosis drug discovery: an industry perspective.
    Shirude PS; Ramachandran S; Hosagrahara V
    Future Med Chem; 2013 Apr; 5(5):499-501. PubMed ID: 23573967
    [No Abstract]   [Full Text] [Related]  

  • 14. [Problems of screening of novel antituberculosis antibiotics. 1. Present notions of specific biological properties of human tuberculosis pathogen Mycobacterium tuberculosis].
    Bibikova MV; Borisova NA; Orekhov SN; Katlinskiĭ AV
    Antibiot Khimioter; 2006; 51(1):22-7. PubMed ID: 16734362
    [No Abstract]   [Full Text] [Related]  

  • 15. High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery.
    Christophe T; Ewann F; Jeon HK; Cechetto J; Brodin P
    Future Med Chem; 2010 Aug; 2(8):1283-93. PubMed ID: 21426019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shortening the treatment of tuberculosis.
    Mitchison DA
    Nat Biotechnol; 2005 Feb; 23(2):187-8. PubMed ID: 15696148
    [No Abstract]   [Full Text] [Related]  

  • 17. Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.
    Gumbo T; Pasipanodya JG; Romero K; Hanna D; Nuermberger E
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S25-31. PubMed ID: 26224769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
    van den Boogaard J; Kibiki GS; Kisanga ER; Boeree MJ; Aarnoutse RE
    Antimicrob Agents Chemother; 2009 Mar; 53(3):849-62. PubMed ID: 19075046
    [No Abstract]   [Full Text] [Related]  

  • 19. Welcome to 'Tuberculosis drug discovery and development'.
    D'Oca G
    Future Med Chem; 2010 Aug; 2(8):1241-2. PubMed ID: 21426014
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel and revisited approaches in antituberculosis drug discovery.
    Herrmann J; Rybniker J; Müller R
    Curr Opin Biotechnol; 2017 Dec; 48():94-101. PubMed ID: 28427007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.